Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer cells. We are developing a universal biomarker for enabling oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs.
- Clifford A. Reid, PhD CEO & Co-Founder
- Rob Kimmerling, PhD Director of Research and Development & Co-Founder
- Selim Olcum, PhD Director of Engineering & Co-Founder
- Mark Stevens, PhD Director of Clinical Development & Co-Founder
- Professor Scott Manalis Consultant & Co-Founder